The role of inflammatory stress in acute coronary syndrome

Chinese Medical Journal

Volumn 117, Issue 1, 2004, Pages 133-139

  Shen, Cheng Xing ^a   Chen, Hao Zhu ^b   Ge, Jun Bo ^b  

^a SOUTHEAST UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Acute coronary syndrome; Atherosclerosis; Inflammation

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; ATORVASTATIN; BIOCHEMICAL MARKER; CAPTOPRIL; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPROSARTAN; FIBRINOGEN RECEPTOR ANTAGONIST; FLUINDOSTATIN; GELATINASE B; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; PADGEM PROTEIN; PRAVASTATIN; PROTEIN BCL 2; RAMIPRIL; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; BIOMECHANICS; BLOOD VESSEL WALL; CLINICAL RESEARCH; CLINICAL TRIAL; CORRELATION ANALYSIS; DOSE TIME EFFECT RELATION; DRUG MECHANISM; EVIDENCE BASED MEDICINE; HEART MUSCLE ISCHEMIA; HUMAN; IMMUNOMODULATION; INFLAMMATION; MEDICAL LITERATURE; MEDLINE; NONHUMAN; OXIDATIVE STRESS; PROSPECTIVE STUDY; REVIEW;

ANGINA PECTORIS; ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; BLOOD VESSELS; HUMANS; INFLAMMATION; MYOCARDIAL INFARCTION; STRESS; SYNDROME;

EID: 1242284456     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Burke AP, Farb A, Malcom GT, et al. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997;336:1276-1282.
2. Lee RT, Libby P. The unstable atheroma. Arterioscler Thromb Vasc Biol 1997;17:1859-1867.
3. Herrick J. Certain clinical features of sudden obstruction of the coronary arteries. Trans Am Assoc Physicians 1912;27: 100-116.
4. Fuster V, Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 1994;90:2126-2146.
5. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-126.
6. Fuster V, Fayad ZA, Badimon JJ. Acute coronary syndromes: biology. Lancet 1999;353(Suppl II) :SII5-SII9.
7. Lindmark E, Diderholm E, Wallentin L, et al. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA 2001;286:2107-2113.
8. Treasure C, Klein J, Weintraub W, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332:481-487.
9. S Investigators. Randomised trial of cholesterol lowering in 4 444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
10. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
11. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study Investigators. N Engl J Med 2000;342:145-153.
12. Greaves DR, Gordon S. Immunity, atherosclerosis and cardiovascular disease. Trends Immunol 2001;22:180-181.
13. Bobryshev YV. Can dendritic cells be exploited for therapeutic intervention in atherosclerosis Atherosclerosis 2001;154:511-512.
14. Aukrust P, Waehre T, Damas JK, et al. Inflammatory role of platelets in acute coronary syndromes. Heart 2001;86:605-606.
15. Ikonomidis I, Andreotti F, Economou E, et al. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999;100: 793-798.
16. Mallat Z, Besnard S, Duriez M, et al. Protective role of interleukin-10 in atherosclerosis. Circ Res 1999;85:e17-e24.
17. Fruebis J, Gonzalez V, Silvestre M, et al. Effect of probucol treatment on gene expression of VCAM-1, MCP-1, and M-CSF in the aortic wall of LDL receptor-deficient rabbits during early atherogenesis. Arterioscler Thromb Vasc Biol 1997;17: 1289-1302.
18. Natarajan R, Reddy MA, Malik et al. Signaling mechanisms of nuclear factor-kappab-mediated activation of inflammatory genes by 13-hydroperoxyoctadecadienoic acid in cultured vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2001;21:1408-1413.
19. Ritchie ME. Nuclear factor-κB is selectively and markedly activated in humans with unstable angina pectoris. Circulation 1998;98:1707-1713.
20. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 2002;53:31-47.
21. Thom DH, Wang SP, Grayston JT, et al. Chlamydia pneumoniae strain TWAR antibody and angiographically demonstrated coronary artery disease. Arterioscler Thromb 1991;11:547-551.
22. Jackson LA, Campbell LA, Schmidt RA, et al. Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: evaluation of the innocent bystander hypothesis. Am J Pathol 1997;150:1785-1790.
23. Blum A, Giladi M, Weinberg M, Kaplan G, et al. High anti-cytomegalovirus (CMV) IgG antibody titer is associated with coronary artery disease and may predict post-coronary balloon angioplasty restenosis. Am J Cardiol 1998;81:866-868.
24. Shi Y, Tokunaga O. Herpes virus (HSV-1, EBV and CMV) infections in atherosclerotic compared with non-atherosclerotic aortic tissue. Pathol Int 2002;52:31-39.
25. Pieniazek P, Karczewska E, Duda A, et al. Association of Helicobacter pylori infection with coronary heart disease. J Physiol Pharmacol 1999;50:743-751.
26. Stroka DM, Badrichani AZ, Bach FH, et al. Overexpression of A1, an NF-kappaB-inducible anti-apoptotic bcl gene, inhibits endothelial cell activation. Blood 19991; 93: 3803-3810.
27. Sorescu D, Szocs K, Griendling KK. NAD (P) H oxidases and their relevance to atherosclerosis. Trends Cardiovasc Med 2001;11:124-131.
28. Marathe GK, Prescott SM, Zimmerman GA, et al. Oxidized LDL contains inflammatory PAF-like phospholipids. Trends Cardiovasc Med 2001;11:139-142.
29. Inoue T, Uchida T, Kamishirado, H, et al. Clinical significance of antibody against oxidized low density lipoprotein in patients with atherosclerotic coronary artery disease. J Am Coll Cardiol 2001;37:775-779.
30. Albert CM, Ma J, Rifai N, et al. Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation. 2002;105: 2595-2599.
31. Haverkate F, Thompson SG, Pyke SD, et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina: European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997; 349:462-466.
32. Pietil KO, Harmoinen AP, Jokiniitty J, et al. Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur Heart J 1996; 17:1345-1349.
33. de Winter RJ, Fischer J, Bholasingh R, et al. C-Reactive protein and cardiac troponin T in risk stratification: differences in optimal timing of tests early after the onset of chest pain. Clin Chem 2000;46:1597-1603.
34. Moukarbel GV, Arnaout MS, Alam SE. C-reactive protein is a marker for a complex culprit lesion anatomy in unstable angina. Clin Cardiol 2001;24:506-510.
35. Passoni F, Morelli B, Seveso G, et al. Comparative short-term prognostic value of hemostatic and inflammatory markers in patients with non-ST elevation acute coronary syndromes. Ital Heart J 2002;3:28-33.
36. Ikeda U, Ito T, Shimada K. Interleukin-6 and acute coronary syndrome. Clin Cardiol 2001;24:701-704.
37. Mallat Z, Corbaz A, Scoazec A, et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation. 2001;104:1598-1603.
38. Blankenberg S, Tiret L, Bickel C, et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002;106:24-30.
39. van der Wal AC, Piek JJ, de Boer OJ, et al. Recent activation of the plaque immune response in coronary lesions underlying acute coronary syndromes. Heart 1998;80:14-18.
40. Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001;103: 491-495.
41. Haim M, Tanne D, Boyko V, et al. Soluble intercellular adhesion molecule-1 and long-term risk of acute coronary events in patients with chronic coronary heart disease. Data from the bezafibrate infarction prevention (BIP) study. J Am Coll Cardiol 2002;39:1133-1138.
42. Ridker PM, Rifai N, Braunwald E, et al. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000; 101: 2149-2153.
43. Inokubo Y, Hanada H, Ishizaka H, et al. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 2001; 141:211-217.
44. Bayes-Genis A, Conover CA, Overgaard MT, et al. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med 2001;345:1022-1029.
45. Cyrus T, Sung S, Zhao L, et al. Effect of Low-Dose Aspirin on Vascular Inflammation, Plaque Stability, and Atherogenesis in Low-Density Lipoprotein Receptor-Deficient Mice. Circulation 2002;106:1282-1287.
46. Gurfinkel E, Bozovich G, Beck E, et al. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study. Eur Heart J 1999;20:121-127.
47. Sander D, Winbeck K, Klingelhofer J, et al. Reduced progression of early carotid atherosclerosis after antibiotic treatment and Chlamydia pneumoniae seropositivity. Circulation 2002;106:2428-2433.
48. Onozato ML, Tojo A, Goto A, et al. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB. Kidney Int 2002;61:186-194.
49. Bellosta S, Via D, Canavesi M, et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 1998;18:1671-1678.
50. Ikeda U, Shimpo M, Ohki R, et al. Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells. Hypertension 2000;36:325-329.
51. Kimura M, Kurose I, Russell J, et al. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats. Arterioscler Thromb Vasc Biol 1997;17:1521-1526.
52. Weber C, Erl W, Weber KS, et al. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 1997; 30: 1212-1217.
53. Bustos C, Hernandez-Presa MA, Ortego M, et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 1998;32:2057-2064.
54. Niwa S, Totsuka T, Hayashi S. Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. Int J Immunopharmacol 1996;18:669-675.
55. Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1999;353:983-984.
56. Ferro D, Parrotto S, Basili S, et al. Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol 2000;36:427-431.
57. Riesen WF, Engler H, Risch M, et al. Short-term effects of atorvastatin on C-reactive protein. Eur Heart J 2002;23:794-799.
58. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events (CARE) investigators. Circulation 1998;98:839-844.
59. Ridker PM, Rifai N, Braunwald E, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The cholesterol and recurrent events (CARE) investigators. Circulation 1999;100:230-235.
60. Wassmann S, Laufs U, Baumer AT, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001;37:1450-1457.
61. Hernandez-Presa M, Bustos C, Ortego M, et al. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 1997;95:1532-1541.
62. Kranzhofer R, Schmidt J, Pfeiffer CA, et al. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999;19:1623-1629.
63. Soejima H, Ogawa H, Yasue H, et al. Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction. J Am Coll Cardiol 1999;34:983-988.
64. Rahman ST, Lauten WB, Khan QA, et al. Effects of eprosartan versus hydrochlorothiazide on markers of vascular oxidation and inflammation and blood pressure (renin-angiotensin system antagonists, oxidation, and inflammation). Am J Cardiol 2002;89:686-690.
65. Biasucci LM, Liuzzo G, Colizzi C, et al. Clinical use of C-reactive protein for the prognostic stratification of patients with ischemic heart disease. Ital Heart J 2001;2:164-171.
66. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-1965.
67. Brown BG, Zhao XQ, Sacco DE, et al. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993;87:1781-1791.
68. Ambrose JA. Martinez EE. A new paradigm for plaque stabilization. Circulation 2002;105:2000-2004.